T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E 2 ) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the eects of E 2 and triiodothyronine (T 3 ) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon con¯uency, the cells were treated with T 3 (10 712 to 10 77 M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E 2 treatment of cells caused a 2 ± 3-fold increase in the level of p53. Presence of T 3 in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS ± PAGE) in the presence of E 2 and T 3 . Supplementation of growth medium with T 3 (1 mM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this eect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 mM), an ER antagonist, was combined with E 2 (1 nM) or T 3 (1 mM), eects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal uorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T 3 for the [ 3 H]E 2 binding. These results indicate that T 3 regulates T47D cell cycle progression and proliferation raising the p53 level and causing hyperphosphorylation of pRb by a common mechanism involving ER and T 3 receptor (T 3 R)-mediated pathways.
T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E 2 ) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the eects of E 2 and triiodothyronine (T 3 ) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon con¯uency, the cells were treated with T 3 (10 712 to 10 77 M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E 2 treatment of cells caused a 2 ± 3-fold increase in the level of p53. Presence of T 3 in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS ± PAGE) in the presence of E 2 and T 3 . Supplementation of growth medium with T 3 (1 mM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this eect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 mM), an ER antagonist, was combined with E 2 (1 nM) or T 3 (1 mM), eects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal uorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T 3 for the [ Introduction Dierent hormones in¯uence the development, growth and dierentiation of human breast tissue. The two steroid hormones, E 2 and progesterone, impact cellular functioning of the normal breast cells and may continue to be active in its malignant state. It has been well established that nearly 30% of breast cancers are hormone-dependent and respond well to endocrine therapy (Clarke and Sutherland, 1990; Horwitz, 1985 Horwitz, , 1992 . Although the relationship between breast cancer and the more active form of thyroid hormone, T 3 , is not known, T 3 appears to stimulate lobular development and contribute to the dierentiation of normal breast tissue (Burke and McGuire, 1978) .
The products of tumor suppressor genes, p53 and pRb, appear to play important roles in the incidence, progression or management of breast cancer (Hurd et al., 1995 (Hurd et al., , 1997 . pRb plays a major role in the control of cell division and dierentiation. Active form of pRb is hypophosphorylated and present in quiescent G1 phase cells (White, 1994; Weinberg, 1995) . Tumor suppressor function of pRb is lost due to its hyperphosphorylation causing it to dissociate from the mitogenic factor E2F. Mutations in the p53 gene have been reported in over 50% of breast and colon cancers (Oren, 1992) . The main function of p53 is to switch o replication of damaged DNA allowing its repair, or induce apoptosis to disrupt cell proliferation.
The T47D breast cancer cell line is ER and progesterone receptor (PR)-positive and expresses p53 with a missense mutation at codon 194 converting leucine to phenylalanine in the protein (Nigro et al., 1989) . We had previously reported that E 2 regulates the expression of p53 and the state of phosphorylation of pRb in breast cancer cells (Hurd et al., 1997) . There is, however, a paucity of information about the regulation of tumor suppressors or proto-oncogenes by thyroid and steroid hormones. Although abundance of c-Fos protein has been shown to be in¯uenced by thyroid hormones (Lin et al., 1999) . It has been proposed that these hormones may act via their nuclear receptors to in¯uence proto-oncogene expression (Franklyn and Sheppard, 1989) . E 2 -like eects of T 3 have been observed in a variety of experimental systems, including the in¯uence of these hormones in the healthy tissues or breast cancer cells (Franklyn and Sheppard, 1989; Shao et al., 1995; Blohmer et al., 1999; Parhar et al., 2000; Qi et al., 1997; Dellovade et al., 1999 Dellovade et al., , 2000 Morgan et al., 2000; Barrera-Hernandez et al., 1999) . Thyroid hormone-induced cell proliferation in rat pituitary GC cells has been reported to be mediated by cyclin/cyclin-dependent kinase (CDK) activity (Barrera-Hernandez et al., 1999) . Physiological concentrations of T 3 appear to enhance estrogen stimulation of growth of breast carcinoma, which is blocked by the addition of ligands inducing retinoid X receptor (RXR) homodimers (Shao et al., 1995) . Thyroid hormones have also been reported to either in¯uence or interfere with the estrogen-stimulated female reproductive behavior (Dellovade et al., 1999 Morgan et al., 2000) . It has been proposed that T 3 R interacts with p53 in vivo to reverse p53-induced suppression of promoter activity (Qi et al., 1997) . A cross talk between p53 and ER has been suggested in hormone-activated signaling pathways (Bhat et al., 1997) . Although the published studies addressed the inter-relationships between T 3 and p53 or T 3 -induced cell proliferation and estrogen in¯uences, eorts to incorporate all these variants in a single system and under similar experimental conditions have been lacking and were initially reported from this laboratory (Dinda et al., 1998) . The present study focuses on (a) the eects of E 2 , T 3 and antiestrogen (ICI) on the regulation of p53 and pRb, (b) the eects of E 2 , T 3 and ICI on the proliferation of T47D cells, and (c) to examine the correlation, if any, between immunolocalization and expression of p53 with the cell proliferation.
Results
Regulation of p53 and pRb by T 3 : Time course and concentration dependency Trace amounts of endogenous steroids, including E 2 , are routinely removed from media by treatment of serum with charcoal suspension (stripped) in order to monitor the eects of exogenously added ligands (Hurd et al., 1995) . Recently, our laboratory has shown the levels of p53 and the degree of phosphorylation of pRb are maximal at a 24 h treatment of T47D cells cultured in media containing stripped serum supplemented with E 2 (1 nM) (Hurd et al., 1997 . The hyperphosphorylation of pRb occurred between 12 and 24 h in T47D cells. In this study, we have compared the eects of 1 nM E 2 and T 3 within a broad range of hormone concentrations (10 712 ± 10 77 M) on the levels of p53 and pRb. Equal number of cells were plated in whole serum (containing endogenous E 2 ) for 2 days and then maintained for 6 days in stripped serum containing media. The cells were treated with the hormones for 24 h. Figure 1 demonstrates the time course regulation of p53 and pRb by T 3 . The level of p53 grown in stripped serum medium is generally low when compared with its level in cell grown in whole serum (Hurd et al., 1995 (Hurd et al., , 1997 . In the present studies, cells were grown in stripped serum and the level of p53 in these cells provided the base line value. Supplementation of culture medium with 1 mM T 3 resulted in a 220% increase in the level of p53 over a period of 24 h with a maximum (400%) at 8 h (Figure 1, upper panel) . We have previously shown that rise in p53 following E 2 supplementation is an early event (Hurd et al., 1995) . The pRb protein was resolved into a rapidly migrating lower band corresponding to a hypophosphorylated active proliferation suppressing form (pRb), and a slower migrating upper band corresponding to a hyperphosphorylated form (ppRb) (Figure 1, lower panel) . Cells grown in stripped serum medium exhibited mainly the hypophosphorylated pRb (control, C). Treatment of cells with T 3 caused hyperphosphorylation of pRb in a time-dependent manner exhibiting a maximum between 4 ± 12 h ( Figure  1 , lower panel). The increase in p53 level in cells treated with T 3 for 1 h could represent both transcriptional and post-transcriptional mechanisms. The latter may involve stabilization of p53 but such investigations were neither performed nor considered in the scope of this work. Figure 2 demonstrates eects of dierent concentrations of T 3 on the level of p53 and degree of phosphorylation of pRb. The levels of p53 in the control (C, stripped serum) samples were low but detectable. Treatment of cells with increasing concentrations of T 3 raised the level of p53 in a gradual manner showing a maximum near 1 ± 10 nM ( Figure 2 , upper panel). The p53 level in the cells treated with T 3 was equivalent to that seen in cells treated with 1 nM E 2 . When the degree of phosphorylation of pRb was analysed under these conditions, pRb was observed to exist mainly in its hypophosphorylated pRb form Figure 1 Regulation of p53 and pRb by T 3 : Time course. Cells were plated into medium containing 5% serum for 2 days and then withdrawn from E 2 stimuli by culturing them for 7 days in medium containing charcoal-treated serum. Cells grown in stripped serum were then treated with 1 mM concentration of T 3 for 0 ± 24 h as represented in the ®gure. The control is represented by C (grown in charcoal-treated serum) and had no hormone treatment. High salt protein extracts were prepared and quantity of p53 and pRb were determined by SDS ± PAGE (8%) and Western analysis 
Coordinate regulation of pRb phosphorylation and upregulation p53 by hormones and antihormones
In order to determine the mechanism of T 3 and E 2 actions in T47D cells which contribute to the observed eects on p53 and pRb, the in¯uence of full ER antagonist, ICI was examined. T47D cells were cultured for 6 days in stripped serum and then treated with E 2 (1 nM) and T 3 (1 mM) in the absence and presence of ICI (1 mM). We have previously shown the level of p53 decreases in cells grown in stripped serum compared with when grown in whole serum (Hurd et al., 1995 (Hurd et al., , 1997 . Figure 3 , (upper panel) shows supplementation of culture medium with E 2 and T 3 resulted in an increase in the level of p53 expression. The potent antiestrogen ICI blocked both the E 2 and T 3 -induced eects on p53 levels. Treatment with E 2 and T 3 also caused pRb hyperphosphorylation ( Figure  3 , lower panel), which is associated with the cell proliferation. ICI (1 mM) was able to block the E 2 -induced phosphorylation as indicated by the signi®cant loss of the upper band of pRb. Similarly, ICI was able to downshift the T 3 -induced ppRb form to its pRb hypophoshorylated form.
The Western analyses in the studies were supplemented by image analysis by confocal microscopy involving immuno¯uorescence localization of cellular p53. Results in Figure 4 demonstrate that p53 is exclusively localized in the T47D cell nuclei under all conditions of testing. Treatment of cells with either hormone increased the intensity of nuclear staining of p53 in T47D cells. When cells were exposed to both hormones simultaneously, the degree of immuno¯uor-escence was only marginally greater than when eects of hormones were tested separately. Again, ICI blocked the extent of immuno¯uorescence generated by the treatment of cells with both the ligands. The nuclear staining of p53 indicates that E 2 , T 3 and antiestrogens do not aect the localization of p53 in T47D cells (under the conditions of testing), but rather the accumulation of nuclear p53. The density of nuclear¯uorescence correlated well with the protein levels determined by Western analysis.
Effects of T 3 on the proliferation of T47D cells
We next assessed the eects of E 2 , T 3 and the antiestrogens on the T47D cell proliferation in order to correlate this with pRb hyperphosphorylation and cellular level of p53. Cells were treated with ligands as described earlier and in Methods. T47D cell proliferation was determined by cell counting ( Figure 5 ). Culturing cells in stripped serum reduced the cell population by 46% (compared to controls in stripped versus whole serum) (not shown) suggesting that charcoal treatment removed factor(s) required for maximal T47D cell proliferation (Hurd et al., 1995 (Hurd et al., , 1997 Iwasaki et al., 1999) . It is known charcoal Figure 2 Regulation of p53 and pRb by T 3 : Concentration dependency. Cells were plated into medium containing 5% serum for 2 days and then withdrawn from E 2 stimuli by culturing them for 7 days in medium containing charcoal-treated serum. The control is represented by C (grown in charcoal-treated serum) and had no hormone treatment. The cells were then treated for 24 h with E 2 (1 nM) and T 3 concentrations (10 712 ± 10 77 M). High salt protein extracts were resolved by SDS ± PAGE (8%), transferred to a PVDF protein blotting membrane and probed with primary antibodies; puri®ed anti-human pRb clone G3-245 (PharMingen), anti-p53 monoclonal antibody (Transduction) and secondary HRP-conjugated anti-mouse IgG. Bands were visualized by enhanced chemiluminescence (ECL) Figure 3 Eects of E 2 , T 3 , and antiestrogen (ICI) on the phosphorylation of pRb and induction of p53. Cells were plated into medium containing 5% serum for 2 days and then withdrawn from E 2 stimuli by culturing them for 7 days in medium containing charcoal-treated serum. C represents control grown in strip serum and received no hormone treatment. Cells were treated with E 2 (1 nM), T 3 (1 mM), and combinations of E 2 (1 nM) or T 3 (1 mM) plus ICI (1 mM). High salt protein extracts were prepared and the quantity of p53 and pRb were determined by SDS ± PAGE (8%) and Western analysis Oncogene Thyroid hormone regulation of p53 and pRb S Dinda et al treatment removes T 3 /T 4 as well as steroids in addition to a variety of other hormones and growth factors. E 2 addition increased the cell count consistent with the increased p53 expression during the E 2 -induced proliferative state (Hurd et al., 1995 (Hurd et al., , 1997 Iwasaki et al., 1999) . The addition of E 2 and T 3 caused a signi®cant increase (104 and 577%, respectively) in the cell count. The E 2 eect on proliferation re¯ects our earlier ®ndings (Hurd et al., 1995 (Hurd et al., , 1997 Iwasaki et al., 1999) and those expected from thyroprival cells exposed to E 2 . The combination of E 2 and T 3 did not increase the cell number signi®cantly compared to E 2 and T 3 , individually suggesting absence of a synergistic mechanism with regard to cell proliferation, and perhaps re¯ecting a physiological eect. The antiestrogen, ICI, inhibited E 2 and T 3 -dependent cell proliferation. Since ICI is also capable of inhibiting T 3 R in the absence of added E 2 which could be explained on the basis of bar 5 in Figure 5 . Whether ICI blocks some of the primary genomic eects of T 3 in T47D cells is not known. It was not the focus of this work to directly link p53 and cell proliferation. The increase in cell proliferation was studied more as a mark of estrogen action than its association with wild or mutated p53. Both forms of p53 could be induced, yet the increase in the mutated form would be nonfunctional. T47D cells express a mutated p53 with a missence mutation at codon 194 (Nigro et al., 1989) . Shih et al. (2001) have shown that T 4 causes ser-15 phosphorylation of p53. Whether p53 phosphorylation was also in¯uenced by treatment of T47D cells by E 2 and T 3 will be a target for future studies. 
Discussion
The clinical signi®cance of the in¯uence of thyroid hormone in breast cancer has not been established with certainty (Cerbon et al., 1981) . It has been Figure 4 Cytolocalization of p53 in T47D cells by immuno¯uorescence. Cells in triplicate were plated in 12-well growth (30 000 cells/well) on cover slips cultured for 2 days in whole serum and then treated with 1 nM E 2 , 100 nM 4 hydroxy-tamoxifen (OHT), 1 mM ICI (ICI) or 1 mM tamoxifen (TAM) or cultured in stripped serum supplemented with 1 nM E 2 plus antiestrogens. Fresh media and ligands were replaced at 2 day intervals. p53 localization was determined by Immuno-labeling and laser scanning confocal uorescence microscopy Figure 5 Eects of E 2 , T 3 , and antiestrogens on the proliferation of T47D cancer cells. Cells (30 000) were plated in a 12-well plate for 2 days in medium containing 5% bovine serum. The cells were withdrawn from E 2 stimuli by culturing for 6 days in medium containing stripped serum and the ligands. The medium and the ligands were replaced at 2 day intervals. After 7 days in the presence of E 2 , T 3 , and the antiestrogens, the cell number was determined by Coulter Counter (model #Z2). Error bars represent standard deviations of triplicate cell counts
Thyroid hormone regulation of p53 and pRb S Dinda et al suggested that hypothyroidism is a risk factor for the development of breast cancer (Alvarado-Pisani et al., 1986). The main aim of the present study was to compare the eects of E 2 and T 3 on the regulation of p53 and pRb in breast cancer cells. The p53 and pRb are key factors regulating proliferation of breast cancer cells. We had previously demonstrated that culturing T47D cells in stripped serum decreases the level of p53 by 90%, and a supplementation with a physiological concentration of E 2 (0.1 ± 1 nM) was sucient to maintain high levels of p53 (Hurd et al., 1995) . A physiological concentration of E 2 was sucient to stimulate both p53 expression and pRb phosphorylation. We have shown that T 3 treatment increased the level of p53 and caused hyperphosphorylation of pRb. The proliferative eects of E 2 on the breast epithelial cells are well documented and appear to be mediated by the cyclin D1-cdk 2/4-Rb pathway (Dulic et al., 1994; El-Deiry et al., 1993; Wa®k et al., 1994) . It has been reported that p53-dependent transactivation of the cdk inhibitor p 21WAF1/CIP1 attenuates pRb phosphorylation and thus cell cycle progression from G1 to S phase of the cell cycle (Xiong et al., 1993) . Although the role of T 3 in the progression of breast cancer is not established, E 2 and T 3 -dependent p53 expression could in¯uence breast epithelial cell proliferation. Mutation, loss or insucient expression of p53 during breast cell proliferation could theoretically contribute to breast cancer development by default of p53-mediated cell arrest or apoptosis. It is not clear whether the levels of p53 are regulated by E 2 and T 3 or if indirect signals emitted by proliferating cells, in general, regulate p53.
The rate of proliferation of T47D cells and the levels of p53 decline to a minimal state in cells grown in culture medium containing charcoal-stripped serum. Supplementation of media with exogenous E 2 or T 3 enhances, but does not recover the maximum rate of proliferation of cells grown in medium containing whole serum. E 2 and T 3 induce p53 to near maximal levels which is independent of the proliferation state.
Furthermore, the kinetics of p53 expression relative to pRb phosphorylation suggests that this occurs during G1 phase of the cycle where p53 can attenuate pRb phosphorylation.
We have observed that ICI blocked the E 2 and T 3 induced expression of p53 and hyperphosphorylation of pRb in T47D breast cancer cells. These data may imply an ER-mediated mechanism for T 3 -induced p53 expressions and hyperphosphorylation of pRb. Steroid binding analysis has shown that T 3 does not compete with E 2 for binding to ER in T47D cells. E 2 and T 3 have been reported to compete for ER binding in MCF-7 cells (Nogueria and Brentani, 1996) . In the absence of T 3 R, the thyroid hormone response element (TRE) can act as an imperfect estrogen response element (ERE) and mediate E 2 -dependent activation of transcription (Dellovade et al., 1995) . These data suggest the possibility of existence of complex interactions between estrogen and thyroid hormones and their in¯uence on gene expression. Alternatively, T 3 -bound T 3 R may stimulate ERE function in T47D cells eliciting E 2 -like eects. The latter observation is supported by the assumption that ER and T 3 R bind to parts of the same hormone-response elements of target genes (Dellovade et al., 1995) .
We propose a hypothesis to explain the observed estrogen-like eects of thyroid hormone. T 3 R and ER bind to dierent parts of the same hormone response elements of a target gene and compete with each other for inducing a response. By this mechanism, ER and T 3 R interactions would have stimulatory or inhibitory eects depending on the absence or presence of ligands, and the consequences of protein-DNA interactions (Dellovade et al., 1995; Graupner et al., 1991) . It has been proposed that E 2 -like eects of thyroid hormone are possibly in¯uenced by events which occur subsequent to the process of steroid binding (Dellovade et al., 1999 . The noted E 2 -like proliferative eects of T 3 in our study have revealed an unexplored potential of thyroid hormones in breast cancer patients undergoing T 3 treatment. Further work in this area should help provide insight into the mode of action of T 3 in T47D cells as well as its potential clinical relevance in breast cancer.
In summary, we propose a uni®ed model of the regulation of p53 and pRb by E 2 and T 3 in breast cancer cells (Figure 7) . Accordingly, E 2 binding to ER leads to the formation of steroid-receptor complex that interacts with EREs in the T47D cell genome. Since ER is a nuclear transcription factor, and E 2 is a known regulator of gene expression, a number of hormonesensitive genes are known to be in¯uenced by hormone treatment of T47D cells. We have previously shown that E 2 stimulates c-Myc in T47D and MCF-7 cell lines (Shao et al., 1995) . A speci®c E 2 -dependent ERmediated c-Myc species was induced, which was sensitive to full ER antagonist, ICI. We believe, among other possibilities, the eects of E 2 are mediated via cMyc expression since E 2 was shown to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element (Reisman et al., 1988) . The estrogen-like eects of T 3 appear to be mediated via T 3 R interaction with ERE to stimulate gene expression since T 3 does not appear to compete for the E 2 binding to ER (Figure 6 ). This postulation is now being tested in the laboratory.
The tumor suppressor activity of wild type p53 is expressed via its ability to cause DNA repair, induce apoptosis or synthesis of inhibitor of cyclin-cyclindependent kinase, p21. The latter blocks cell division. These functions are compromised in cells containing mutated p53, which can lead to cell proliferation. In its active tumor suppressor form, pRb exists as the hypophosphorylated entity. Results of our earlier studies (Hurd et al., 1995 (Hurd et al., , 1997 and reported here (Figures 1 ± 3) have shown E 2 causes hyperphosphorylation of pRb and increasing cell proliferation. The exact nature of the kinase(s) involved in the estrogen-induced hyperphosphorylation is not known and is a target of our future studies. A number of additional possibilities exist as to the role of hormones in the regulation of tumor suppressors and protooncogenes. T 3 /T 4 could complex p53 with MAPK and with TR (Shih et al., 2001 ). An interaction between TR and p53 was suggested earlier (Bhat et al., 1997; Qi et al., 1997 , Yap et al., 1996 . The complexing of TR by p53 could then decrease the transcriptional activity of p53. Phosphorylation of ER by MAPK has been shown to result in serine phosphorylation of the latter (Kato et al., 1995) . Thus it is possible ER and T 3 R may interact in T47D cells in the presence of T 3 and E 2 to in¯uence p53 activity. Should this become probable after further experimentation, it will necessitate reevaluation of our model (Figure 7 ). A hypothetical model for explaining regulation of p53 and pRb by E 2 and T 3 in T47D breast cancer cells. ER, estrogen receptor; ERE, estrogen response elements; P, phosphorylation; pRb, retinoblastoma protein; T 3 R, thyroid hormone receptor routinely cultured at 378C in an incubator in RPMI 1640 media with L-glutamine supplemented with 5% heat inactivated fetal bovine serum (FBS) or single stripped fetal bovine serum (SSFBS), 25 mM HEPES, 24 mM sodium bicarbonate, 0.5% 1006non-essential amino acids, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 0.25 mg/ml amphotericin B, and 0.14 IU/ml insulin. Stock solutions of the ligand were prepared in ethanol to a 1000-fold higher concentration than the ®nal concentrations during cell treatment. Aliquots (10 ml) of ligand were added directly to 10 ml of media. Controls contained identical quantities of ethanol vehicle as cells treated with ligands. Media and ligands were added fresh at 2-day intervals. For proliferation studies, cells were passed into triplicate Corning 12-well dishes. After treatments with E 2 , T 3 (ICN Pharmaceuticals Inc., Costa Mesa, CA, USA) or the antiestrogen, cell number was determined by Coulter counter model Z2 as previously described (Hurd et al., 1997 , Kodali et al., 1994 alone or plus 1 mM and 1 nM of E 2 , and with dierent concentrations of T 3 (1, 10, 100, 1000 nM). Cells were placed in an incubator for 2 h prior to preparation of protein extracts. An equal volume of Dextran-coated charcoal solution (0.5% charcoal, 0.05% Dextran T-70 in 10 mM Tris, 1 mM EDTA, pH 7.4) was added to 150 ml of protein extract, the solution vortexed and incubated on ice for 5 min. Charcoal suspension was pelleted by centrifugation at 3000 g for 5 min at 48C. The radioactivity in 150 ml of supernatant was determined by scintillation counting.
Materials and methods

Materials
Extraction of proteins from T47D cells
Media was removed by aspiration, the cells were washed with 10 ml ice-cold Hanks balanced salt solution (HBSS), and the cells were then scraped into 500 ml of extraction buer (20 mM HEPES, 50 mM NaF, 10 mM Na 2 MoO 4 , 8 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , 40 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM leupeptin, 30 mg/ml pepstatin-A, 30 mg/ml chymostatin and 0.3 mM PMSF). Cells were burst by the freeze/thaw method via immersion in liquid nitrogen for 20 s and thawed on ice. This was repeated three times. After the ®nal thaw, the cell suspension was brought to a ®nal ionic strength of 0.5 M by addition of 4.0 M NaCl, 20 mM HEPES, pH 7.4 and incubated on ice for 1 h with gentle resuspension of the pellet. A high speed supernatant (HSS) of the extract was prepared via centrifugation of the burst cells at 35 000 r.p.m. for 45 min at 48C. HSS was frozen in liquid nitrogen and stored at 7808C until further use.
SDS ± PAGE and Western blot analysis
High speed supernatants were denatured and 75 mg of total protein/lane [quanti®ed by the Bio-Rad Laboratories (Hercules, CA, USA) protein assay kit] were resolved on an 8% polyacrylamide gel under denaturing conditions. Proteins were transferred to Immobilon PVDF membrane (Millipore) at 30 Volts for 14 h or 60 Volts for 7 h in a Tris glycine buer system containing 0.025% SDS and 15% methanol using a Bio-Rad trans blot cell with tap water cooling. Membranes were blocked for 1 h in TBS-tween (0.1%) plus 5% Carnation instant non-fat dry milk, then probed for 1 h in the same solution containing a 1 : 500 dilution of primary antibodies, anti-p53 monoclonal antibody (Transduction Laboratories) or a 1 : 500 dilution of puri®ed anti-human pRb, clone G3-245 (PharMingen). The membrane was then washed for 30 min with three changes of TBS-tween, reblocked for 30 min with TBS-tween plus 5% Carnation instant non-fat dry milk and then incubated in the same solution plus a 1 : 1000 dilution of HRP-conjugated antimouse IgG H+L chain (Boehringer Mannheim). After a ®nal wash, p53 speci®c bands were visualized by the enhanced chemiluminescence (ECL) method according to the instructions from Amersham.
Immunolabeling and laser scanning confocal fluorescence microscopy Cells were plated in triplicate in 12-well growth plates (30 000 cells/well) on cover slips prior to treatment with E 2 or the antiestrogens for 7 day treatment periods. Subsequent incubations were performed at 238C. The cells were ®xed on cover slips for 10 min with 1% formalin in PBS, air dried with ice-cold acetone: methanol (50 : 50) for 3 min and then washed 3X with PBS. Staining procedures were performed in a humidi®ed chamber at 238C. Nonspeci®c binding of IgG was suppressed by incubating cells for 20 min in 10% goat serum. Cells were then incubated with primary anti-p53 Ab (Signal Transduction) at a 1 : 150 dilution for 2 h, washed 4X with PBS and then incubated with secondary Ab, anti-mouse IgG conjugated to FITC (Sigma) at 1 : 150 dilution and then washed 56 with PBS and mounted in Fluoromount-G according to instruction from Electron Microscopy Sciences (FT. Washington, PA 19034). The distribution of threedimensional¯uorescent structures were analysed using a BioRad 600 laser scanning Confocal microscope and photographed with a Nikon Optiphot microscope. Fluorescence images were collected under a 406 objective sequentially using a Krypton argon (488 nm) laser beam for excitation and a broad pass (514 ± 545 nm) emission ®lter. COSMOS software (Bio-Rad) was used for the collection of images. The image dimensions were approximately 5126512 pixels with 8-bits of resolution. Software`Confocal assistant' was used for pseudocolor restitution. Fluorescence images were obtained by pseudocolor image restitution from gray scale images.
Abbreviations ATCC, American type culture collection; E 2 , 17-b estradiol; ECL, enhanced chemiluminescence; ERE, estrogen response element; FBS, fetal bovine serum; ER, estrogen receptor; HBSS, Hanks' balanced salt solution; HSS, high speed supernatant; ICI, ICI 164 384; OHT, 4-hydroxy tamoxifen; p53, 53-kDa tumor suppressor protein; PBS, phosphatebuered saline; PMSF, phenylmethylsulfonyl¯uoride; PVDF, polyvinylidene¯uoride; PR, progesterone receptor; pRb, retinoblastoma protein; ppRb, phosphorylated pRb; Rb, retinoblastoma; SDS ± PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SSFBS, single stripped fetal bovine serum; T 3 , triiodothyronine; TAM, tamoxifen; T 3 R, thyroid hormone receptor; TRE, thyroid hormone response element.
